Group items tagged

The latest findings from the National Cancer Patient Experience Survey 2022 by QualityWatch, a joint programme with the Nuffield Trust and the Health Foundation shed light on concerning disparities faced by ethnic minority communities in the UK healthcare system. Despite strides in cancer care, the survey highlights persistent challenges in easy and equitable access to timely diagnosis and quality communication, particularly for individuals from Mixed, Black, or Asian backgrounds. Key insights from the survey underscored that individuals from ethnic minority groups often require a higher number of interactions with healthcare professionals before receiving a cancer diagnosis. Notably, one in three people from Mixed, Black, or Asian ethnicities needed three or more visits to a GP practice, compared to the average of one in five across the population. These delays in diagnosis can have significant implications for treatment outcomes and overall patient experience. Moreover, the survey revealed concerning trends regarding the quality of communication following a cancer diagnosis among ethnic minority patients.

Despite being the most common genetic disorder in the UK, sickle cell disease (SCD) remains significantly underfunded and underserved compared to other genetic disorders, according to a new report published by the PDA BAME (Black, Asian and Minority Ethnic) Pharmacists' Network. The report also reveals that the disease is poorly understood within the healthcare system, including amongst pharmacists, pharmacy students, and foundation pharmacists in the UK. It emphasises the urgent need for increased awareness, funding, and improved healthcare access for SCD amongst these healthcare professionals. "A lack of education about SCD within the wider healthcare community, including pharmacy, greatly contributes to disparities in care. "Though the importance of SCD education for pharmacists and allied healthcare professionals is acknowledged, it remains unclear whether this topic is adequately addressed within the MPharm curriculum," the report said. The report further noted that in the absence of explicit guidance from the General Pharmaceutical Council (GPhC) or the Pharmaceutical Society of Northern Ireland (PSNI) and without more comprehensive education surrounding SCD embedded within the pharmacy curriculum, pharmacists and future pharmacists may remain "ill-prepared to manage patients with this complex condition." As per the report, sickle cell disease is the most prevalent genetic disorder globally, impacting millions, including around 17,000 people in England.